{"id":"vx-809","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"VX-809 corrects the function of the CFTR protein by binding to the protein and facilitating its proper folding and trafficking to the cell surface. This increases the amount of functional CFTR protein on the cell surface, which helps to restore normal chloride transport across epithelial cells.","oneSentence":"VX-809 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:57.245Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cystic fibrosis"}]},"trialDetails":[{"nctId":"NCT03894657","phase":"NA","title":"Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-12-18","conditions":"Cystic Fibrosis, Homozygous F508del Mutation","enrollment":91},{"nctId":"NCT04732910","phase":"","title":"Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2018-07-01","conditions":"Cystic Fibrosis","enrollment":500},{"nctId":"NCT03587961","phase":"EARLY_PHASE1","title":"Personalized Theratyping Trial","status":"RECRUITING","sponsor":"George Solomon","startDate":"2019-08-01","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT03475381","phase":"","title":"Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-01-22","conditions":"Cystic Fibrosis","enrollment":852},{"nctId":"NCT04970225","phase":"NA","title":"Cystic Fibrosis Blood Neutrophils","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-08","conditions":"Cystic Fibrosis","enrollment":47},{"nctId":"NCT04581408","phase":"PHASE2","title":"Mutation-specific Therapy for the Long QT Syndrome","status":"COMPLETED","sponsor":"Istituto Auxologico Italiano","startDate":"2021-06-15","conditions":"Long QT Syndrome","enrollment":16},{"nctId":"NCT04235140","phase":"PHASE3","title":"Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2020-02-24","conditions":"Cystic Fibrosis","enrollment":52},{"nctId":"NCT02965326","phase":"NA","title":"Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients","status":"RECRUITING","sponsor":"Hôpital Necker-Enfants Malades","startDate":"2016-05","conditions":"Cystic Fibrosis","enrollment":75},{"nctId":"NCT03445793","phase":"","title":": TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2018-03-01","conditions":"Cystic Fibrosis (CF)","enrollment":5},{"nctId":"NCT05968612","phase":"PHASE1","title":"Bioequivalence and Food Effect Bioavailability Study of Lumacaftor Film-Coated Tablets","status":"COMPLETED","sponsor":"Qanatpharma Canada LTD","startDate":"2023-11-17","conditions":"Healthy Volunteer","enrollment":39},{"nctId":"NCT04415268","phase":"NA","title":"Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis","status":"WITHDRAWN","sponsor":"Universidad Europea de Madrid","startDate":"2020-06-09","conditions":"Cystic Fibrosis in Children","enrollment":""},{"nctId":"NCT04138589","phase":"","title":"Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2017-11-01","conditions":"Cystic Fibrosis in Children","enrollment":30},{"nctId":"NCT03601637","phase":"PHASE3","title":"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-09-07","conditions":"Cystic Fibrosis","enrollment":61},{"nctId":"NCT03625466","phase":"PHASE2","title":"A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2018-08-10","conditions":"Cystic Fibrosis","enrollment":51},{"nctId":"NCT05526027","phase":"NA","title":"Real-world Efficacy and Safety of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy in Adult Patients With Cystic Fibrosis (CF)","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-09-01","conditions":"Cystic Fibrosis","enrollment":85},{"nctId":"NCT03795363","phase":"","title":"Orkambi Treatment in 2 to 5 Year Old Children With CF","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2019-04-10","conditions":"Cystic Fibrosis","enrollment":28},{"nctId":"NCT03512119","phase":"","title":"Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-02-11","conditions":"Cystic Fibrosis Homozygous for Phe 508 Del CFTR, Glucose Intolerance or Newly Diagnosis Diabetes","enrollment":55},{"nctId":"NCT02709109","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Parion Sciences","startDate":"2016-02","conditions":"Cystic Fibrosis","enrollment":147},{"nctId":"NCT02544451","phase":"PHASE3","title":"Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":246},{"nctId":"NCT04301856","phase":"","title":"Response to CFTR Modulators in CF Patients Under 18 Years","status":"UNKNOWN","sponsor":"Societe Francaise de la Mucoviscidose","startDate":"2020-01-01","conditions":"Cystic Fibrosis in Children","enrollment":600},{"nctId":"NCT04623879","phase":"","title":"Real Life Evaluation of the Multi-organ Effects of Lumacaftor/Ivacaftor on F508del Homozygous Cystic Fibrosis Patients.","status":"COMPLETED","sponsor":"Carmel Medical Center","startDate":"2016-12-29","conditions":"Cystic Fibrosis","enrollment":13},{"nctId":"NCT03125395","phase":"PHASE3","title":"A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-05-12","conditions":"Cystic Fibrosis","enrollment":57},{"nctId":"NCT02807415","phase":"","title":"ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2016-06-01","conditions":"Cystic Fibrosis","enrollment":104},{"nctId":"NCT03140527","phase":"PHASE1","title":"Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis","status":"COMPLETED","sponsor":"Proteostasis Therapeutics, Inc.","startDate":"2017-04-10","conditions":"Healthy Volunteer, Cystic Fibrosis","enrollment":171},{"nctId":"NCT03565692","phase":"","title":"Lum-Iva-biota: Exploring the Respiratory Mycobiota and Microbiota Profile in French CF Patients Taking Lumacaftor-Ivacaftor","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2018-07-01","conditions":"Cystic Fibrosis","enrollment":250},{"nctId":"NCT03956589","phase":"PHASE4","title":"Functional Respiratory Imaging and Orkambi in CF","status":"TERMINATED","sponsor":"University Hospital, Antwerp","startDate":"2018-10-01","conditions":"Cystic Fibrosis","enrollment":12},{"nctId":"NCT03150719","phase":"PHASE3","title":"A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-05-24","conditions":"Cystic Fibrosis","enrollment":98},{"nctId":"NCT02653027","phase":"NA","title":"Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2018-01-01","conditions":"Diabetes, Cystic Fibrosis","enrollment":""},{"nctId":"NCT02875366","phase":"PHASE4","title":"A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-09","conditions":"Cystic Fibrosis","enrollment":70},{"nctId":"NCT02797132","phase":"PHASE3","title":"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-05","conditions":"Cystic Fibrosis","enrollment":62},{"nctId":"NCT03061331","phase":"PHASE2","title":"Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2017-01-31","conditions":"Cystic Fibrosis","enrollment":20},{"nctId":"NCT02823470","phase":"PHASE4","title":"A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2016-06","conditions":"Cystic Fibrosis","enrollment":24},{"nctId":"NCT02858843","phase":"NA","title":"The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2016-08-01","conditions":"Cystic Fibrosis, Diabetes","enrollment":1},{"nctId":"NCT02390219","phase":"PHASE3","title":"Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-03","conditions":"Cystic Fibrosis, Advanced Lung Disease","enrollment":46},{"nctId":"NCT02514473","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2015-07","conditions":"Cystic Fibrosis","enrollment":206},{"nctId":"NCT01897233","phase":"PHASE3","title":"Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-07","conditions":"Cystic Fibrosis","enrollment":62},{"nctId":"NCT01931839","phase":"PHASE3","title":"A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-10","conditions":"Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation","enrollment":1164},{"nctId":"NCT02589236","phase":"PHASE2","title":"Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Nivalis Therapeutics, Inc.","startDate":"2015-11","conditions":"Cystic Fibrosis","enrollment":138},{"nctId":"NCT01807949","phase":"PHASE3","title":"A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-04","conditions":"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation","enrollment":563},{"nctId":"NCT01225211","phase":"PHASE2","title":"Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2010-10","conditions":"Cystic Fibrosis","enrollment":312},{"nctId":"NCT01807923","phase":"PHASE3","title":"A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-05","conditions":"Cystic Fibrosis, Homozygous for the F508del CFTR Mutation","enrollment":559},{"nctId":"NCT00865904","phase":"PHASE2","title":"Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2009-03","conditions":"Cystic Fibrosis","enrollment":93},{"nctId":"NCT01910415","phase":"PHASE1","title":"Phase 1, QT/QTC Interval Study in Healthy Subjects","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-06","conditions":"Cystic Fibrosis","enrollment":200},{"nctId":"NCT01899105","phase":"PHASE1","title":"A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-07","conditions":"Cystic Fibrosis","enrollment":28},{"nctId":"NCT01888393","phase":"PHASE1","title":"Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-06","conditions":"Hepatic Impairment, Healthy","enrollment":23},{"nctId":"NCT01768663","phase":"PHASE1","title":"A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2013-01","conditions":"Cystic Fibrosis","enrollment":80},{"nctId":"NCT01216046","phase":"PHASE1","title":"Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2010-10","conditions":"Cystic Fibrosis","enrollment":48},{"nctId":"NCT00966602","phase":"PHASE1","title":"Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy Subjects","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2009-09","conditions":"Cystic Fibrosis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":198,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lumacaftor"],"phase":"phase_3","status":"active","brandName":"VX-809","genericName":"VX-809","companyName":"Vertex Pharmaceuticals Incorporated","companyId":"vertex-pharmaceuticals-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VX-809 is a cystic fibrosis transmembrane conductance regulator (CFTR) corrector. Used for Cystic fibrosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}